Digitala Vetenskapliga Arkivet

Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
The 2023 yearbook of Neurorestoratology
Beijing Hongtianji Neurosci Acad, Cell Therapy Ctr, Beijing 100143, Peoples R China..
Rutgers State Univ, Univ Hosp, Ctr Ventilator Management Alternat, New Jersey Med Sch,Dept Phys Med & Rehabil, Newark, NJ 07102 USA..
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Surgical Sciences, Anaesthesiology and Intensive Care.ORCID iD: 0000-0002-6595-5903
Beijing Univ Tradit Chinese Med, Dongzhimen Hosp, Dept Neurosurg, Beijing 100007, Peoples R China..
Show others and affiliations
2024 (English)In: JOURNAL OF NEURORESTORATOLOGY, ISSN 2324-2426, Vol. 12, no 3, article id 100136Article, review/survey (Refereed) Published
Abstract [en]

Remarkable advancements have been made in understanding the pathogenesis of Alzheimer's disease, Parkinson's disease, and other neurological disease; in our depth of understanding neurorestorative mechanisms such as anti-inflammatory processes, immune regulation, neuromodulation, neovascularization/neural repair, and neuroprotection; and in clinical neurorestorative treatments. Multiple types of cell therapies have been reported, with some positive outcomes. Diverse forms of neurostimulation and neuromodulation as well as brain-computer interfaces have shown good therapeutic outcomes in clinical applications. Further, therapeutic neurorestorative surgery and pharmaceutic therapy have been very impressive. These fundamental achievements are helpful for understanding the pathogenesis of neurological diseases and the mechanisms of neurorestoration. Patients with neurological impairments have benefited from therapeutic progress, but some of these therapies still require confirmation in higher-level randomized clinical trials.

Place, publisher, year, edition, pages
Elsevier, 2024. Vol. 12, no 3, article id 100136
Keywords [en]
Pathogenesis of neurological diseases, Neurorestorative mechanisms, Clinical neurorestorative treatments, Cell therapy, Neurostimulation and neuromodulation, Brain -computer interfaces
National Category
Neurology Neurosciences
Identifiers
URN: urn:nbn:se:uu:diva-536803DOI: 10.1016/j.jnrt.2024.100136ISI: 001273816600001OAI: oai:DiVA.org:uu-536803DiVA, id: diva2:1893561
Available from: 2024-08-29 Created: 2024-08-29 Last updated: 2024-08-29Bibliographically approved

Open Access in DiVA

fulltext(369 kB)80 downloads
File information
File name FULLTEXT01.pdfFile size 369 kBChecksum SHA-512
9a42d7d946437273df651b1da1c759c562e1061ecd1ec334041e492713541d431b207c78bc2587d5b489ed322c9aa1ba40d26a14cef39a903e5ddfc3e9146478
Type fulltextMimetype application/pdf

Other links

Publisher's full text

Search in DiVA

By author/editor
Sharma, Hari Shanker
By organisation
Anaesthesiology and Intensive Care
NeurologyNeurosciences

Search outside of DiVA

GoogleGoogle Scholar
Total: 80 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

doi
urn-nbn

Altmetric score

doi
urn-nbn
Total: 134 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf